Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment

Kreft, Karim L. and Robertson, Neil P. ORCID: https://orcid.org/0000-0002-5409-4909 2022. Innovative biomarkers to predict unfavourable outcomes after initiating multiple sclerosis treatment. Journal of Neurology 269 (9) , pp. 5192-5193. 10.1007/s00415-022-11300-x

PDF - Published Version Download (362kB)

Abstract

Over the last decade, more than ten new disease modifying treatments (DMTs) for multiple sclerosis (MS) have been approved and introduced into routine clinical care. All have demonstrated improved efficacy in limiting ongoing inflammation and tissue damage in MS patients, but many have potentially serious side effect profiles that require more careful monitoring than previous baseline therapies. Together with the tendency for earlier introduction of high efficacy DMTs, the risk that patients will encounter adverse events will increase over time. Identifying biomarkers which enable accurate prediction of prognosis and treatment response has become a major challenge to those working in the field. In this journal club, we describe three novel studies aiming to predict and detect serious side effects associated with MS treatments.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher:	Springer
ISSN:	0340-5354
Date of First Compliant Deposit:	11 August 2022
Date of Acceptance:	18 July 2022
Last Modified:	23 May 2023 16:00
URI:	https://orca.cardiff.ac.uk/id/eprint/151892

Actions (repository staff only)

Edit Item